We hypothesized that the combined use of leukoreduction and avoidance of infusion of ABO-incompatible antibodies or antigens would reduce both the need for HLA-matched platelets and the development of ...
Second-line (2L) pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Three-year follow up (FU) of the phase 1 KEYNOTE-151 study. This is an ASCO Meeting Abstract from the 2021 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results